Table of Contents
Advances in Endocrinology
Volume 2014 (2014), Article ID 503846, 11 pages
http://dx.doi.org/10.1155/2014/503846
Review Article

Endogenous Glucagon-Like Peptide-1 as a Potential Mediator of the Resolution of Diabetic Kidney Disease following Roux en Y Gastric Bypass: Evidence and Perspectives

1Diabetes Complications Research Centre, Conway Institute of Biomolecular and Biomedical Research, School of Medicine and Medical Sciences, University College Dublin, Belfield, Dublin 4, Ireland
2Gastrosurgical Laboratory, University of Gothenburg, Sweden
3Investigative Science, Imperial College London, UK

Received 27 April 2014; Revised 1 August 2014; Accepted 25 August 2014; Published 18 September 2014

Academic Editor: James M. Lenhard

Copyright © 2014 Neil G. Docherty and Carel W. Le Roux. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Afkarian, M. C. Sachs, B. Kestenbaum et al., “Kidney disease and increased mortality risk in type 2 diabetes,” Journal of the American Society of Nephrology, vol. 24, no. 2, pp. 302–308, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Li, P. Zhang, L. E. Barker, F. M. Chowdhury, and X. Zhang, “Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review,” Diabetes Care, vol. 33, no. 8, pp. 1872–1894, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. A. I. Adler, R. J. Stevens, S. E. Manley, R. W. Bilous, C. A. Cull, and R. R. Holman, “Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64),” Kidney International, vol. 63, no. 1, pp. 225–232, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. S. G. Coca, F. Ismail-Beigi, N. Haq, H. M. Krumholz, and C. R. Parikh, “Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis,” Archives of Internal Medicine, vol. 172, no. 10, pp. 761–769, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. R. J. Macisaac, E. I. Ekinci, and G. Jerums, “Markers of and risk factors for the development and progression of diabetic kidney disease,” American Journal of Kidney Diseases, vol. 63, pp. S39–S62, 2014. View at Google Scholar
  6. UK Prospective Diabetes Study (UKPDS) Group, “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33),” The Lancet, vol. 352, no. 9131, pp. 837–853, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. R. R. Holman, S. K. Paul, M. A. Bethel, D. R. Matthews, and H. A. W. Neil, “10-Year follow-up of intensive glucose control in type 2 diabetes,” New England Journal of Medicine, vol. 359, no. 15, pp. 1577–1589, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Ruggenenti, P. Cravedi, and G. Remuzzi, “The RAAS in the pathogenesis and treatment of diabetic nephropathy,” Nature Reviews: Nephrology, vol. 6, no. 6, pp. 319–330, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. B. E. de Galan, V. Perkovic, T. Ninomiya et al., “Lowering blood pressure reduces renal events in type 2 diabetes,” Journal of the American Society of Nephrology, vol. 20, no. 4, pp. 883–892, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. B. M. Brenner, M. E. Cooper, D. De Zeeuw et al., “Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy,” The New England Journal of Medicine, vol. 345, no. 12, pp. 861–869, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Gæde, H. Lund-Andersen, H.-H. Parving, and O. Pedersen, “Effect of a multifactorial intervention on mortality in type 2 diabetes,” New England Journal of Medicine, vol. 358, no. 6, pp. 580–591, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. S. A. Brethauer, A. Aminian, H. Romero-Talamas et al., “Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus,” Annals of Surgery, vol. 258, pp. 628–637, 2013. View at Google Scholar
  13. H. Buchwald, R. Estok, K. Fahrbach et al., “Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis,” The American Journal of Medicine, vol. 122, no. 3, pp. 248.e5–256.e5, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Sjöström, A.-K. Lindroos, M. Peltonen et al., “Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery,” The New England Journal of Medicine, vol. 351, no. 26, pp. 2683–2693, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Sjöström, K. Narbro, C. D. Sjöström et al., “Effects of bariatric surgery on mortality in Swedish obese subjects,” The New England Journal of Medicine, vol. 357, no. 8, pp. 741–752, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. K. J. Neff, A. H. Frankel, F. W. Tam, D. M. Sadlier, C. Godson, and C. W. le Roux, “The effect of bariatric surgery on renal function and disease: a focus on outcomes and inflammation,” Nephrology Dialysis Transplantation, vol. 28, supplement 4, pp. 73–82, 2013. View at Google Scholar
  17. A. Iaconelli, S. Panunzi, A. de Gaetano et al., “Effects of bilio-pancreatic diversion on diabetic complications: a 10-year follow-up,” Diabetes Care, vol. 34, no. 3, pp. 561–567, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Navarro-Díaz, A. Serra, R. Romero et al., “Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up,” Journal of the American Society of Nephrology, vol. 17, supplement 3, pp. S213–S217, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Amor, A. Jiménez, V. Moizé et al., “Weight loss independently predicts urinary albumin excretion normalization in morbidly obese type 2 diabetic patients undergoing bariatric surgery,” Surgical Endoscopy, vol. 27, no. 6, pp. 2046–2051, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. W. K. Fenske, S. Dubb, M. Bueter et al., “Effect of bariatric surgery-induced weight loss on renal and systemic inflammation and blood pressure: a 12-month prospective study,” Surgery for Obesity and Related Diseases, vol. 9, no. 4, pp. 559–568, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. B. L. Johnson, D. W. Blackhurst, B. B. Latham et al., “Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus,” Journal of the American College of Surgeons, vol. 216, no. 4, pp. 545–558, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. A. D. Miras, L. L. Chuah, G. Lascaratos et al., “Bariatric surgery does not exacerbate and may be beneficial for the microvascular complications of type 2 diabetes,” Diabetes Care, vol. 35, no. 12, article e81, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. H. M. Heneghan, D. Cetin, S. D. Navaneethan, N. Orzech, S. A. Brethauer, and P. R. Schauer, “Effects of bariatric surgery on diabetic nephropathy after 5 years of follow-up,” Surgery for Obesity and Related Diseases, vol. 9, no. 1, pp. 7–14, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. L. M. Carlsson, S. Romeo, P. Jacobson et al., “The incidence of albuminuria after bariatric surgery and usual care in swedish obese subjects (SOS): a prospective controlled intervention trial,” International journal of obesity, 2014. View at Publisher · View at Google Scholar
  25. D. T. Stephenson, K. Jandeleit-Dahm, B. Balkau, and N. Cohen, “Improvement in albuminuria in patients with type 2 diabetes after laparoscopic adjustable gastric banding,” Diabetes & Vascular Disease Research, vol. 10, pp. 514–519, 2013. View at Google Scholar
  26. B. Jose, S. Ford, P. Super, G. N. Thomas, I. Dasgupta, and S. Taheri, “The effect of biliopancreatic diversion surgery on renal function: a retrospective study,” Obesity Surgery, vol. 23, no. 5, pp. 634–637, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. C.-C. Hou, R.-S. Shyu, W.-J. Lee, K.-H. Ser, Y.-C. Lee, and S.-C. Chen, “Improved renal function 12 months after bariatric surgery,” Surgery for Obesity and Related Diseases, vol. 9, no. 2, pp. 202–206, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. J. M. Cloyd, Y. Ma, J. M. Morton, M. K. Tamura, G. A. Poultsides, and B. C. Visser, “Does chronic kidney disease affect outcomes after major abdominal surgery? Results from the National surgical quality improvement program,” Journal of Gastrointestinal Surgery, vol. 18, no. 3, pp. 605–612, 2014. View at Publisher · View at Google Scholar
  29. M. K. Sinha, M. L. Collazo-Clavell, A. Rule et al., “Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery,” Kidney International, vol. 72, no. 1, pp. 100–107, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Buchwald, Y. Avidor, E. Braunwald et al., “Bariatric surgery: a systematic review and meta-analysis,” The Journal of the American Medical Association, vol. 292, no. 14, pp. 1724–1737, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. W. J. Pories, M. S. Swanson, K. G. MacDonald et al., “Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus,” Annals of Surgery, vol. 222, no. 3, pp. 339–352, 1995. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Mingrone, S. Panunzi, A. De Gaetano et al., “Bariatric surgery versus conventional medical therapy for type 2 diabetes,” The New England Journal of Medicine, vol. 366, no. 17, pp. 1577–1585, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. P. R. Schauer, S. R. Kashyap, K. Wolski et al., “Bariatric surgery versus intensive medical therapy in obese patients with diabetes,” New England Journal of Medicine, vol. 366, no. 17, pp. 1567–1576, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. P. R. Schauer, D. L. Bhatt, J. P. Kirwan et al., “Bariatric surgery versus intensive medical therapy for diabetes - 3-year outcomes,” The New England Journal of Medicine, vol. 370, pp. 2002–2013, 2014. View at Google Scholar
  35. L. M. S. Carlsson, M. Peltonen, S. Ahlin et al., “Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects,” New England Journal of Medicine, vol. 367, no. 8, pp. 695–704, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Castagneto and G. Mingrone, “The effect of gastrointestinal surgery on insulin resistance and insulin secretion,” Current Atherosclerosis Reports, vol. 14, no. 6, pp. 624–630, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Dirksen, N. B. Jørgensen, K. N. Bojsen-Møller et al., “Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass,” Diabetologia, vol. 55, no. 7, pp. 1890–1901, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Maric and J. E. Hall, “Obesity, Metabolic syndrome and diabetic nephropathy,” Contributions to Nephrology, vol. 170, pp. 28–35, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Hallersund, L. Sjöström, T. Olbers et al., “Gastric bypass surgery is followed by lowered blood pressure and increased diuresis: long term results from the Swedish Obese Subjects (SOS) study,” PLoS ONE, vol. 7, no. 11, Article ID e49696, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Hofsø, N. Nordstrand, L. K. Johnson et al., “Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention,” European Journal of Endocrinology, vol. 163, no. 5, pp. 735–745, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Martins, M. Strømmen, O. A. Stavne, R. Nossum, R. Mårvik, and B. Kulseng, “Bariatric surgery versus lifestyle interventions for morbid obesity—changes in body weight, risk factors and comorbidities at 1 year,” Obesity Surgery, vol. 21, no. 7, pp. 841–849, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. Z. Liang, Q. Wu, B. Chen, P. Yu, H. Zhao, and X. Ouyang, “Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trial,” Diabetes Research and Clinical Practice, vol. 101, no. 1, pp. 50–56, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Ikramuddin, J. Korner, W.-J. Lee et al., “Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the diabetes surgery study randomized clinical trial,” The Journal of the American Medical Association, vol. 309, no. 21, pp. 2240–2249, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. A. R. Ahmed, G. Rickards, D. Coniglio et al., “Laparoscopic Roux-en-Y gastric bypass and its early effect on blood pressure,” Obesity Surgery, vol. 19, no. 7, pp. 845–849, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. M. W. Hinojosa, J. E. Varela, B. R. Smith, F. Che, and N. T. Nguyen, “Resolution of systemic hypertension after laparoscopic gastric bypass,” Journal of Gastrointestinal Surgery, vol. 13, no. 4, pp. 793–797, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. J. E. Campbell and D. J. Drucker, “Pharmacology, physiology, and mechanisms of incretin hormone action,” Cell Metabolism, vol. 17, no. 6, pp. 819–837, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. D. S. Shyangdan, P. Royle, C. Clar, P. Sharma, N. Waugh, and A. Snaith, “Glucagon-like peptide analogues for type 2 diabetes mellitus,” Cochrane Database of Systematic Reviews, vol. 5, no. 10, Article ID CD006423, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Astrup, R. Carraro, N. Finer et al., “Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide,” International Journal of Obesity, vol. 36, no. 6, pp. 843–854, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Astrup, S. Rössner, L. van Gaal et al., “Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study,” The Lancet, vol. 374, no. 9701, pp. 1606–1616, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. T. A. Wadden, P. Hollander, S. Klein et al., “Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the Scale Maintenance randomized study,” International Journal of Obesity, vol. 37, pp. 1443–1451, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. V. A. Fonseca, J. H. Devries, R. R. Henry, M. Donsmark, H. F. Thomsen, and J. Plutzky, “Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials,” Journal of Diabetes and Its Complications, vol. 28, no. 3, pp. 399–405, 2014. View at Publisher · View at Google Scholar
  52. M. Shah, J. H. Law, F. Micheletto et al., “Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass,” Diabetes, vol. 63, pp. 483–493, 2014. View at Google Scholar
  53. A. Jiménez, R. Casamitjana, L. Flores, S. Delgado, A. Lacy, and J. Vidal, “GLP-1 and the long-term outcome of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery in morbidly obese subjects,” Annals of Surgery, vol. 257, no. 5, pp. 894–899, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Korner, M. Bessler, W. Inabnet, C. Taveras, and J. J. Holst, “Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding,” Surgery for Obesity and Related Diseases, vol. 3, no. 6, pp. 597–601, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. A. P. Courcoulas, N. J. Christian, S. H. Belle et al., “Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity,” Journal of the American Medical Association, vol. 310, pp. 2416–2425, 2013. View at Google Scholar
  56. M. Bueter, H. Ashrafian, A. H. Frankel, F. W. K. Tam, R. J. Unwin, and C. W. Le Roux, “Sodium and water handling after gastric bypass surgery in a rat model,” Surgery for Obesity and Related Diseases, vol. 7, no. 1, pp. 68–73, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Jiménez, R. Casamitjana, L. Flores et al., “Long-term effects of sleeve gastrectomy and roux-en-y gastric bypass surgery on type 2 diabetes mellitus in morbidly obese subjects,” Annals of Surgery, vol. 256, no. 6, pp. 1023–1029, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. J.-P. Gutzwiller, S. Tschopp, A. Bock et al., “Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men,” The Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 6, pp. 3055–3061, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. R. O. Crajoinas, F. T. Oricchio, T. D. Pessoa et al., “Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1,” The American Journal of Physiology, vol. 301, no. 2, pp. F355–F363, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Rieg, M. Gerasimova, F. Murray et al., “Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice,” The American Journal of Physiology—Renal Physiology, vol. 303, no. 7, pp. F963–F971, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. E. Jensen, “Activation of renal GLP-1 receptors located in the afferent arteriole causes an increase in renal blood flow,” Diabetologia, vol. 56, p. 255, 2013. View at Google Scholar
  62. S. C. Thomson, A. Kashkouli, and P. Singh, “Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat,” American Journal of Physiology: Renal Physiology, vol. 304, no. 2, pp. F137–F144, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Kim, M. J. Platt, T. Shibasaki et al., “GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure,” Nature Medicine, vol. 19, no. 5, pp. 567–575, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. N. Abrahamsson, B. E. Engström, M. Sundbom, and F. A. Karlsson, “Gastric bypass surgery elevates NT-ProBNP levels,” Obesity Surgery, vol. 23, no. 9, pp. 1421–1426, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. J. Klisic, M. C. Hu, V. Nief et al., “Insulin activates Na+/H+ exchanger 3: biphasic response and glucocorticoid dependence,” The American Journal of Physiology—Renal Physiology, vol. 283, no. 3, pp. F532–F539, 2002. View at Google Scholar · View at Scopus
  66. H. Fujita, T. Morii, H. Fujishima et al., “The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential,” Kidney International, vol. 85, pp. 579–589, 2014. View at Google Scholar
  67. H. Hendarto, T. Inoguchi, Y. Maeda et al., “GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases,” Metabolism: Clinical and Experimental, vol. 61, no. 10, pp. 1422–1434, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. A. Ojima, Y. Ishibashi, T. Matsui et al., “Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression,” The American Journal of Pathology, vol. 182, no. 1, pp. 132–141, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. R. Kodera, K. Shikata, H. U. Kataoka et al., “Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes,” Diabetologia, vol. 54, no. 4, pp. 965–978, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. C. W. Park, H. W. Kim, S. H. Ko et al., “Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice,” Journal of the American Society of Nephrology, vol. 18, no. 4, pp. 1227–1238, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. W. J. Liu, S. H. Xie, Y. N. Liu et al., “Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 340, no. 2, pp. 248–255, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. R. Kodera, K. Shikata, T. Takatsuka et al., “Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes,” Biochemical and Biophysical Research Communications, vol. 443, pp. 828–833, 2014. View at Google Scholar
  73. M. L. Alter, I. M. Ott, K. von Websky et al., “DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy,” Kidney & Blood Pressure Research, vol. 36, no. 1, pp. 119–130, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. C. Mega, E. T. de Lemos, H. Vala et al., “Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat),” Experimental Diabetes Research, vol. 2011, Article ID 162092, 12 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. Y. Wang, S. Landheer, W. H. van Gilst et al., “Attenuation of renovascular damage in Zucker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE- and DPP4-inhibitory activity,” PLoS ONE, vol. 7, no. 10, Article ID e46781, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. I. Kawasaki, Y. Hiura, A. Tamai et al., “Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate,” Journal of Diabetes, 2014. View at Publisher · View at Google Scholar
  77. P. H. Groop, M. E. Cooper, V. Perkovic, A. Emser, H. J. Woerle, and M. von Eynatten, “Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction,” Diabetes Care, vol. 36, pp. 3460–3468, 2013. View at Google Scholar
  78. S. Imamura, K. Hirai, and A. Hirai, “The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients,” The Tohoku Journal of Experimental Medicine, vol. 231, pp. 57–61, 2013. View at Google Scholar
  79. L. Varadhan, T. Humphreys, A. B. Walker, C. V. N. Cheruvu, and G. I. Varughese, “Bariatric surgery and diabetic retinopathy: a pilot analysis,” Obesity Surgery, vol. 22, no. 3, pp. 515–516, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. R. Cohen, C. W. Le Roux, D. Papamargaritis et al., “Role of proximal gut exclusion from food on glucose homeostasis in patients with Type 2 diabetes,” Diabetic Medicine, vol. 30, no. 12, pp. 1482–1486, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. C. de Jonge, S. S. Rensen, F. J. Verdam et al., “Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes,” Obesity Surgery, vol. 23, no. 9, pp. 1354–1360, 2013. View at Publisher · View at Google Scholar · View at Scopus